A recent study found that metformin might help overweight teens with Type 1 diabetes lower their A1C scores. Metformin, an oral medication that’s prescribed to treat Type 2 diabetes, helped the teens lower their insulin resistance.
For patients with elevated HbA1c, the use of combination antihyperglycemic medications after inadequate control with metformin alone is commonly prescribed to help patients achieve individualized glycemic levels. Is there actual benefit in dual therapy treatment? Study looks at canagliflozin plus metformin.
The five-year study, called the “Insulin Resistance Intervention after Stroke” trial or “IRIS” trial, investigated the effect of pioglitazone on strokes and heart disease. The results? Compared to a placebo, pioglitazone led to a striking 24% reduction in fatal and non-fatal heart attacks and strokes. Moreover, the rate of new diabetes cases was reduced by […]
A calcium-channel blocker drug that is normally used to treat high blood pressure may also be helpful in treating type 1 and type 2 diabetes, according to a new study from the University of Alabama.
Long-term safety concerns about the drug liraglutide suggest that more studies are needed to assess the risks of this type of medication, according to new research published in Cell Metabolism.
Glucose-lowering agents have a difficult prediction on the mortality of diabetes patients due to the characteristics of the disease state. There is limited data on the impact on survival these agents have. Sulfonylureas and insulin have been associated with increased risk of mortality in diabetes patients. Metformin has a lower mortality risk in patients with […]
When treating patients with type 2 diabetes, it is important to reduce the risk of developing Editcardiovascular disease (CVD). Previous studies have shown that higher HbA1c values are risk factors for CVD. However, previous studies have not shown that glycemic control or treatment with any oral hypoglycemic agent reduces incidence of CVD.
The research, published in a leading journal examined 25,970 patients over ten years and discovered statin users had a higher incidence of diabetes and also weight gain. Patients using the drugs also had more than double the risk of diabetic complications including eye, nerve and kidney damage.
If you’re taking a blood thinner in addition to your antidiabetic medication, you may be more prone to hospitalizations due to falls, insulin shock or an altered mental state, according to a new study.
The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
An FDA safety review on sodium-glucose cotransporter-2 (SGLT-2) inhibitors resulted in additional warnings to the label on ketoacidosis, urosepsis, and pyelonephritis. SGLT-2 are sodium-dependent glucose transport proteins, which can be found in the kidneys.
There’s little difference in the performance of five new once-a-week drugs to treat diabetes when they’re compared to one another, though small differences in side effects emerge, according to a new review of existing evidence.
For people with eye complications from diabetes, the drug Lucentis may be an effective option for preventing serious damage and blindness, according to a new study.
The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) organized a gathering of U.S. and international diabetes physicians, scientists, and other experts to conduct a rigorous examination of potential issues surrounding SGLT2i
Recent research reinforces the notion that metformin may have other benefits, such as helping to prevent certain cancers.
On September 25, 2015, the FDA has approved Tresiba (insulin degludec SC injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart SC injection) as one of the treatment options to improve glycemic controls in adults with diabetes mellitus.
Authors conclude that treatment with Onglyza for type 2 diabetes in older patients was not related with an increased risk of fractures as this was shown by a study encompassing a large population sample. However, an interesting finding between the duration of diabetes and increased risk of bone fracture was discovered, which requires further studies […]
Compared with clinical trial subjects who took a placebo, those who added Jardiance to their regimen of diabetes medications were 38% less likely to die as a result of a heart attack, stroke or other cardiovascular problem during the approximately three years that subjects were tracked.
The revelation, published in the journal Diabetes Care, means that a delayed-release form of metformin that the researchers tested could suit the 40% of type 2 diabetes patients who cannot use the current formulation.
A class of diabetes drugs that include Merck & Co Inc’s Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday.The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006, when […]